skip navigationU S P T O SealUnited States Patent and Trademark Office TTABVUE logo
Home|Site Index|Search|Guides|Contacts|eBusiness|eBiz alerts|News|Help
TTABVUE. Trademark Trial and Appeal Board Inquiry System
v2.4.0

Opposition

Number:91274501Filing Date:02/14/2022
Status:PendingStatus Date:05/15/2023
General Contact Number:571-272-8500
Interlocutory Attorney:ELIZABETH WINTER
Paralegal Name:CHAUNTE T AUSTIN
Defendant
Name:Biocytogen Pharmaceuticals (Beijing) Co.
Correspondence:CYNTHIA JOHNSON WALDEN
FISH & RICHARDSON P.C.
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022
UNITED STATES
tmdoctc@fr.com, mccormick@fr.com, walden@fr.com, kelleher@fr.com, rsmith@fr.com
Phone: 617-542-5070
 
Serial #:88553807Application FileAssignment
Application Status: OPPOSITION PENDING
Mark: RENMAB
Plaintiff
Name:Genmab A/S
Correspondence:MARK LERNER
DUANE MORRIS LLP
230 PARK AVENUE, SUITE 1130
NEW YORK, NY 10169
UNITED STATES
malerner@duanemorris.com, trademarks@duanemorris.com
Phone: 212-404-8714
 
Serial #:76105834Application FileAssignmentRegistration #:2850023
Application Status: REGISTERED AND RENEWED
Mark: GENMAB
 
Serial #:79040923Application FileAssignmentRegistration #:3431559
Application Status: SECTION 71 ACCEPTED
Mark: GENMAB
Prosecution History
#DateHistory TextDue Date
1808/21/2023EXTENSION OF TIME GRANTED
1708/21/2023P MOT FOR EXT W/ CONSENT
1605/15/2023EXTENSION OF TIME GRANTED
1505/15/2023P MOT FOR EXT W/ CONSENT
1403/14/2023SUSPENDED
1303/14/2023P MOT TO SUSP W/ CONSENT PEND SETTL NEGOTIATIONS
1212/19/2022SUSPENDED
1112/19/2022P MOT TO SUSP W/ CONSENT PEND SETTL NEGOTIATIONS
1009/21/2022SUSPENDED
909/21/2022P MOT TO SUSP W/ CONSENT PEND SETTL NEGOTIATIONS
807/14/2022EXTENSION OF TIME GRANTED
707/14/2022P MOT FOR EXT W/ CONSENT
604/20/2022SUSPENDED
504/20/2022P MOT TO SUSP W/ CONSENT PEND SETTL NEGOTIATIONS
403/28/2022ANSWER
302/14/2022INSTITUTED
202/14/2022NOTICE AND TRIAL DATES SENT; ANSWER DUE:03/26/2022
102/14/2022FILED AND FEE
Results as of 09/24/2023 01:07 AM
| .HOME | INDEX| SEARCH | eBUSINESS | CONTACT US | PRIVACY POLICY